227 filings
Page 2 of 12
8-K
GRI
GRI Bio Inc
5 Jan 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7:05pm
DEF 14A
GRI
GRI Bio Inc
Definitive proxy
29 Dec 23
5:57pm
UPLOAD
GRI
GRI Bio Inc
26 Dec 23
Letter from SEC
12:00am
S-1
GRI
GRI Bio Inc
IPO registration
21 Dec 23
5:13pm
PRE 14A
GRI
GRI Bio Inc
Preliminary proxy
20 Dec 23
5:12pm
EFFECT
GRI
GRI Bio Inc
18 Dec 23
Notice of effectiveness
12:15am
424B3
GRI
GRI Bio Inc
15 Dec 23
Prospectus supplement
5:02pm
CORRESP
GRI
GRI Bio Inc
14 Dec 23
Correspondence with SEC
12:00am
8-K
GRI
GRI Bio Inc
5 Dec 23
Clinical development plan potentially leveraging 505(b)(2) regulatory pathway
9:07am
S-1/A
GRI
GRI Bio Inc
IPO registration (amended)
4 Dec 23
4:24pm
CORRESP
GRI
GRI Bio Inc
4 Dec 23
Correspondence with SEC
12:00am
8-K
GRI
GRI Bio Inc
27 Nov 23
Clinical development plan leveraging 505(b)(2) regulatory pathway
8:38am
8-K
GRI
GRI Bio Inc
24 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:04pm
UPLOAD
GRI
GRI Bio Inc
21 Nov 23
Letter from SEC
12:00am
8-K
GRI
GRI Bio Inc
15 Nov 23
Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis ("IPF") on track to start before year end 2023; Interim data expected H1 2024
8:07am
10-Q
2023 Q3
GRI
GRI Bio Inc
Quarterly report
14 Nov 23
12:00am
8-K
GRI
GRI Bio Inc
1 Nov 23
Regulation FD Disclosure
8:45am
S-3
GRI
GRI Bio Inc
Shelf registration
13 Oct 23
4:40pm
4
Leanne M. Kelly
26 Sep 23
GRI BIO / Leanne Kelly ownership change
4:08pm
8-K
GRI
GRI Bio Inc
25 Aug 23
Regulation FD Disclosure
4:42pm